AI-generated summary
The authors conducted a systematic review and meta-analysis of 12 studies combining low-level light therapy and intense pulse light therapy for meibomian gland dysfunction. They report improvements in symptom scores, tear break-up time and Schirmer test results at up to 3 months, with gains sustained at 6 months or longer in a sensitivity analysis. The authors note high heterogeneity between studies and call for further research on long-term safety and comparison with other treatments.
- Studies included
- 12
- Who or what was studied
- Patients with meibomian gland dysfunction
- Limits stated in the abstract
- The abstract reports high heterogeneity across studies (I2 up to 98.6 percent) and that the meibomian gland area reduction was not sustained at 6 months or longer in the two studies reporting it.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Meta-analysis, Systematic review, Low-level laser therapy, Light-emitting diode, Dry eye. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.